Le Lézard
Classified in: Health, Science and technology, Covid-19 virus

Global Recombinant Protein Therapeutics CDMO Market Analysis Report 2023-2030: Increasing Rate of Clinical Research to Boost Demand for Recombinant Protein Therapeutics - ResearchAndMarkets.com


The "Recombinant Protein Therapeutics CDMO Market Size, Share & Trends Analysis Report By Type (Growth Hormones, Interferons, Vaccines, Immunostimulating Agents), By Source, By Indication, By Region, And Segment Forecasts, 2023 - 2030" report has been added to ResearchAndMarkets.com's offering.

The global recombinant protein therapeutics CDMO market size is expected to reach USD 51.95 billion by 2030, expected to grow at a CAGR of 13.9% from 2023 to 2030.

Increasing prevalence of chronic diseases, advancements in biotechnology, the rising prominence of personalized medicine, and increasing biomedical research and development investments are the key factors driving the growth of the market.

The growing demand for recombinant protein therapeutics has increased investment in biopharmaceutical manufacturing infrastructure and facilities. This includes establishing large-scale production facilities, process optimization, and improvements in manufacturing technologies. The expanded manufacturing capacity enables greater production of recombinant protein therapeutics, thereby augmenting the market growth.

The development of recombinant protein drugs in-house can be time-consuming and resource-intensive for biopharmaceutical companies. Outsourcing to CDMOs allows companies to access state-of-the-art facilities, specialized expertise, and optimized processes, resulting in time and cost efficiencies. Contract developers can scale up capabilities and provide quicker turnaround times, enabling biopharmaceutical companies to bring their products to market more promptly.

The COVID-19 pandemic had a considerable impact on the market. The demand for COVID-19 therapies and vaccines expanded the manufacturing capacity for recombinant protein drugs. Several companies focusing on developing recombinant protein therapies have scaled up their processes and facilities to meet the requirements of COVID-19-related products.

This expansion has not only augmented the production of COVID-19 therapies and vaccines but also created opportunities for investment and growth in the recombinant protein therapeutic CDMO industry. For instance, in February 2021, GSK and Sanofi announced the initiation of a Phase 2 trial for the evaluation of their adjuvanted recombinant protein COVID-19 vaccine candidate.

Recombinant Protein Therapeutics CDMO Market Report Highlights

Competitive Landscape

Key Attributes:

Report Attribute Details
No. of Pages 175
Forecast Period 2022 - 2030
Estimated Market Value (USD) in 2022 $18.41 Billion
Forecasted Market Value (USD) by 2030 $51.95 Billion
Compound Annual Growth Rate 13.9%
Regions Covered Global

Key Topics Covered:

Chapter 1. Research Methodology and Scope

Chapter 2. Executive Summary

2.1. Market Outlook

2.2. Segment Outlook

2.3. Competitive Insights

Chapter 3. Recombinant Protein Therapeutics CDMO Market Variables, Trends & Scope

3.1. Market Lineage Outlook

3.1.1. Parent Market Outlook

3.1.2. Related/Ancillary Market Outlook

3.2. Market Dynamics

3.2.1. Market Driver Analysis

3.2.1.1. Increasing Rate of Clinical Research to Boost Demand for Recombinant Protein Therapeutics

3.2.1.2. Rising Adoption of Biologics and Biosimilars

3.2.1.3. Technological Innovations Pertaining to the Development of Novel Recombinant Protein Therapeutics

3.2.2. Market Restraint Analysis

3.2.2.1. Regulatory Hurdles

3.2.2.2. Challenges Related to Quality Control

3.3. Recombinant Protein Therapeutics CDMO Market Analysis Tools

3.3.1. Industry Analysis - Porter's

3.3.2. PESTEL Analysis

3.3.3. COVID-19 Impact Analysis

Chapter 4. Recombinant Protein Therapeutics CDMO Market: Type Estimates & Trend Analysis

4.1. Recombinant Protein Therapeutics CDMO Market, By Type: Segment Dashboard

4.2. Recombinant Protein Therapeutics CDMO Market, By Type: Movement Analysis

4.3. Recombinant Protein Therapeutics CDMO Market Estimates & Forecasts, By Type, 2018 - 2030

4.3.1. Growth Hormones

4.3.2. Interferons

4.3.3. Vaccines

4.3.4. Immunostimulating Agents

4.3.5. Others

Chapter 5. Recombinant Protein Therapeutics CDMO Market: Source Estimates & Trend Analysis

5.1. Recombinant Protein Therapeutics CDMO Market, By Source: Segment Dashboard

5.2. Recombinant Protein Therapeutics CDMO Market, By Source: Movement Analysis

5.3. Recombinant Protein Therapeutics CDMO Market Estimates & Forecasts, By Source, 2018 - 2030

5.3.1. Mammalian Systems

5.3.2. Microbial Systems

Chapter 6. Recombinant Protein Therapeutics CDMO Market: Indication Estimates & Trend Analysis

6.1. Recombinant Protein Therapeutics CDMO Market, By Indication: Segment Dashboard

6.2. Recombinant Protein Therapeutics CDMO Market, By Indication: Movement Analysis

6.3. Recombinant Protein Therapeutics CDMO Market Estimates & Forecasts, By Indication, 2018 - 2030

6.3.1. Oncology

6.3.2. Infectious Diseases

6.3.3. Immunological Disorders

6.3.4. Metabolic Disorders

6.3.5. Haematological Disorders

Chapter 7. Recombinant Protein Therapeutics CDMO Market: Regional Estimates & Trend Analysis

7.1. Regional Market Share Analysis, 2022 & 2030

7.2. Regional Market Dashboard

7.3. Global Regional Market Snapshot

For more information about this report visit https://www.researchandmarkets.com/r/lwid2m

About ResearchAndMarkets.com

ResearchAndMarkets.com is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.


These press releases may also interest you

at 09:50
Sangoma Technologies Corporation ("Sangoma" or the "Company"), a leading provider of managed cloud-based communications and technology solutions for businesses worldwide, is excited to announce its participation at the Centurion One Capital's 7th...

at 09:50
Informatica is launching Informatica® Cloud Data Access Management (CDAM), a solution based on Informatica's 2023 acquisition of Privitar, an industry leader in comprehensive data access management products. Now integrated into the Intelligent Data...

at 09:43
During the 39th annual ADP Meeting of the Minds conference, ADP, a leading global technology company providing human capital management (HCM) solutions, recognized the efforts of five companies in transforming the workplace. These five leaders,...

at 09:36
Inc. magazine revealed that ClassWallet ranks number 49 on its fourth annual Inc. 5000 Regionals: Southeast list, the most prestigious ranking of the fastest-growing Southeast private companies, based in South Carolina, Kentucky, Tennessee, Georgia,...

at 09:35
ViTAA Medical Solutions, Inc., a leading innovator of precision vascular health designed to improve patient outcomes across the globe, is thrilled to announce the appointment of Frank J. Veith, M.D., a distinguished figure in the field of vascular...

at 09:35
CharmHealth, a leading provider of healthcare technology solutions, today announced the winners of its latest CodeRx Hackathon. Open to anyone who loves to code, 1,393 teams competed to create solutions to revolutionize, reimagine and reshape...



News published on and distributed by: